SVF
Level C· Early Human ResearchProspective Study

Implantation of human mesenchymal stromal cell pellet for therapeutic angiogenesis.

Mammoto A., Kyi P., Scheer M., Mammoto T.

Prospective Study with a reported sample of 237 on Face & Skin, Systemic / IV, published in Cytotherapy (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cytotherapy (2026)
Country
England
Reported sample size
237
PMID
41421145
DOI
10.1016/j.jcyt.2025.102009

Abstract (original English)

Although mesenchymal stromal cell (MSC) therapy holds great potential, therapeutic efficacy, which is predicted by pre-clinical studies, has fallen short of expectations in most clinical studies. This discrepancy may arise from inadequate standardization of cell preparations, unstable cell engraftment and insufficient understanding of cellular fitness in vivo due to the lack of a relevant experimental system in which human MSCs stably engraft and the behavior of the MSCs can be systemically analyzed. MSCs stimulate angiogenesis and accelerate tissue/organ regeneration by releasing various bioactive factors (secretome). In this study, we established a system in which an implanted human MSC pellet stably engrafts and the angiogenic ability of the MSCs can be systematically analyzed in vivo. Surgically excised human subcutaneous white adipose tissue (4 g) was enzymatically digested and MSCs were successfully isolated from 237 patients (19-91 years old). MSCs isolated from donors (13 clones) less than 65 years old were used for the experiments. MSCs stimulated sprouting of human adipose endothelial cells in endothelial cell-organoids in vitro. Various angiogenesis-related factors were detected in cell lysate and conditioned medium from cultured non-frozen human MSCs in vitro. Within 21 days after initial cell isolation, an implantable MSC pellet was created by culturing human MSCs

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
HumansMesenchymal Stem CellsAnimalsMesenchymal Stem Cell TransplantationNeovascularization, PhysiologicAdultMiddle AgedFemaleMiceAged
Face & SkinSystemic / IV
View on PubMedDOI

Related research